– Form 8 Filing
FDA Again Highlights Lacking Data From Amylyx’s Amyotrophic Lateral Sclerosis Candidate
The FDA released briefing documents for Amylyx Pharmaceuticals Inc’s (NASDAQ:AMLX) experimental amyotrophic lateral sclerosis drug, as a second adcomm is scheduled…